Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Temsirolimus probably leads to lower overall survival survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (moderate certainty).
Temsirolimus may leads to lower serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
It is very uncertain whether sunitinib changes overall survival (absolute effect size estimates based on survival… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with atezolizumab (targeted therapy versus immunotherapy) (moderate certainty).
Bevacizumab + IFN probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
Bevacizumab + IFN may leads to lower overall survival (absolute effect size estimates based on survival… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (low certainty).
Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
The review found no eligible studies for this question.
Temsirolimus + IFN‐α may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + IFN‐α showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + IFN‐α may leads to higher serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).
Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether everolimus + bevacizumab changes progression‐free survival (absolute effect size estimates based on… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).